<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font28 { font-size : 28; } .font12 { font-size : 12; } .font29 { font-size : 29; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">patients </span>
   <span class="font29">migraine </span>
   <span class="font28">headache </span>
   <span class="font18">study </span>
   <span class="font18">Headache </span>
   <span class="font17">(.) </span>
   <span class="font17">treatment </span>
   <span class="font16">chronic </span>
   <span class="font16">University </span>
   <span class="font15">Correspondence: </span>
   <span class="font15">clinical </span>
   <span class="font15">pain </span>
   <span class="font14">compared </span>
   <span class="font14">Department </span>
   <span class="font14">aura </span>
   <span class="font14">erenumab </span>
   <span class="font14">frequency </span>
   <span class="font14">sleep </span>
   <span class="font13">Hospital, </span>
   <span class="font13">Results: </span>
   <span class="font13">group </span>
   <span class="font13">reported </span>
   <span class="font13">episodic </span>
   <span class="font13">weeks </span>
   <span class="font13">mean </span>
   <span class="font13">number </span>
   <span class="font13">reduction </span>
   <span class="font13">symptoms </span>
   <span class="font13">Background: </span>
   <span class="font13">Methods: </span>
   <span class="font13">Neurology </span>
   <span class="font13">Neurology, </span>
   <span class="font13">higher </span>
   <span class="font13">score </span>
   <span class="font13">trials </span>
   <span class="font13">days </span>
   <span class="font12">associated </span>
   <span class="font12">fremanezumab </span>
   <span class="font12">significantly </span>
   <span class="font12">(.%) </span>
   <span class="font12">data </span>
   <span class="font12">migraine. </span>
   <span class="font12">monthly </span>
   <span class="font12">HIT- </span>
   <span class="font12">Medical </span>
   <span class="font12">significant </span>
   <span class="font12">total </span>
   <span class="font12">Medicine, </span>
   <span class="font12">baseline </span>
   <span class="font12">headache. </span>
   <span class="font12">Discussion: </span>
   <span class="font12">TTH </span>
   <span class="font12">included </span>
   <span class="font12">primary </span>
   <span class="font12">using </span>
   <span class="font12">age </span>
   <span class="font12">showed </span>
   <span class="font12">Inc., </span>
   <span class="font12">medication </span>
   <span class="font12">months </span>
   <span class="font12">prior </span>
   <span class="font12">received </span>
   <span class="font12">vs. </span>
   <span class="font12">{border-style </span>
   <span class="font12">MMDs </span>
   <span class="font12">National </span>
   <span class="font12">Novartis </span>
   <span class="font12">consciousness </span>
   <span class="font12">diagnosis </span>
   <span class="font12">headaches </span>
   <span class="font11">Patients </span>
   <span class="font11">analysis </span>
   <span class="font11">brain </span>
   <span class="font11">month </span>
   <span class="font11">patient </span>
   <span class="font11">px;} </span>
   <span class="font11">results </span>
   <span class="font11">use </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">Clinical </span>
   <span class="font11">PPTF </span>
   <span class="font11">characteristics </span>
   <span class="font11">diagnostic </span>
   <span class="font11">loss </span>
   <span class="font11">patients. </span>
   <span class="font11">subjects </span>
   <span class="font11">Athens, </span>
   <span class="font11">College </span>
   <span class="font11">MMD </span>
   <span class="font11">Migraine </span>
   <span class="font11">did </span>
   <span class="font11">disease </span>
   <span class="font11">greater </span>
   <span class="font11">migraine, </span>
   <span class="font11">overuse </span>
   <span class="font11">response </span>
   <span class="font11">scores </span>
   <span class="font11">used </span>
   <span class="font11">visual </span>
   <span class="font11">association </span>
   <span class="font11">participants </span>
   <span class="font11">present </span>
   <span class="font11">preventive </span>
   <span class="font11">studies </span>
   <span class="font11">typical </span>
   <span class="font11">Department, </span>
   <span class="font11">Hospital </span>
   <span class="font11">Impact </span>
   <span class="font11">Novartis, </span>
   <span class="font11">according </span>
   <span class="font11">cluster </span>
   <span class="font11">criteria </span>
   <span class="font11">duration </span>
   <span class="font11">efficacy </span>
   <span class="font11">identified </span>
   <span class="font11">increased </span>
   <span class="font11">intensity </span>
   <span class="font11">lower </span>
   <span class="font11">performed </span>
   <span class="font11">placebo </span>
   <span class="font11">years </span>
   <span class="font11">-., </span>
   <span class="font11">.). </span>
   <span class="font11">CI: </span>
   <span class="font11">Health </span>
   <span class="font11">Pain </span>
   <span class="font11">Research </span>
   <span class="font11">United </span>
   <span class="font11">aim </span>
   <span class="font11">cases </span>
   <span class="font11">connectivity </span>
   <span class="font11">nocebo </span>
   <span class="font11">observed </span>
   <span class="font11">research </span>
   <span class="font11">thresholds </span>
   <span class="font11">time </span>
   <span class="font11">trigeminal </span>
   <span class="font11">(mg), </span>
   <span class="font11">Center, </span>
   <span class="font11">Group, </span>
   <span class="font11">However, </span>
   <span class="font11">Lilly, </span>
   <span class="font11">Rome, </span>
   <span class="font11">Teva </span>
   <span class="font11">average </span>
   <span class="font11">case </span>
   <span class="font11">cases, </span>
   <span class="font11">change </span>
   <span class="font11">common </span>
   <span class="font11">decreased </span>
   <span class="font11">different </span>
   <span class="font11">disability </span>
   <span class="font11">evidence </span>
   <span class="font11">headache, </span>
   <span class="font11">high </span>
   <span class="font11">including </span>
   <span class="font11">poor </span>
   <span class="font11">population </span>
   <span class="font11">post-traumatic </span>
   <span class="font11">prevalence </span>
   <span class="font11">quality </span>
   <span class="font11">study. </span>
   <span class="font11">support </span>
   <span class="font11">values </span>
   <span class="font11">CGRP </span>
   <span class="font11">Results </span>
   <span class="font11">University, </span>
   <span class="font11">WA, </span>
   <span class="font11">adverse </span>
   <span class="font11">anti-CGRP </span>
   <span class="font11">burden </span>
   <span class="font11">conducted </span>
   <span class="font11">control </span>
   <span class="font11">controls </span>
   <span class="font11">difference </span>
   <span class="font11">effect </span>
   <span class="font11">impact </span>
   <span class="font11">items </span>
   <span class="font11">pediatric </span>
   <span class="font11">prophylactic </span>
   <span class="font11">type </span>
   <span class="font11">&amp;lt; </span>
   <span class="font11">(%) </span>
   <span class="font11">(weeks </span>
   <span class="font11">Alder </span>
   <span class="font11">Allergan </span>
   <span class="font11">Allergan, </span>
   <span class="font11">Boston, </span>
   <span class="font11">CM, </span>
   <span class="font11">Center </span>
   <span class="font11">Eli </span>
   <span class="font11">Greece </span>
   <span class="font11">Italy; </span>
   <span class="font11">Kapodistrian </span>
   <span class="font11">Korea </span>
   <span class="font11">MOH </span>
   <span class="font11">PACAP </span>
   <span class="font11">School </span>
   <span class="font11">Table </span>
   <span class="font11">Unit, </span>
   <span class="font11">attack </span>
   <span class="font11">consulting </span>
   <span class="font11">depression </span>
   <span class="font11">development </span>
   <span class="font11">following </span>
   <span class="font11">increase </span>
   <span class="font11">literature </span>
   <span class="font11">management </span>
   <span class="font11">mild </span>
   <span class="font11">months. </span>
   <span class="font11">network </span>
   <span class="font11">onabotulinumtoxinA </span>
   <span class="font11">pooled </span>
   <span class="font11">psychological </span>
   <span class="font11">quarterly </span>
   <span class="font11">relationship </span>
   <span class="font11">responses </span>
   <span class="font11">scale </span>
   <span class="font11">severe </span>
   <span class="font11">systematic </span>
   <span class="font11">treated </span>
   <span class="font11">treatments </span>
   <span class="font10">(,%) </span>
   <span class="font10">.±. </span>
   <span class="font10">Barcelona, </span>
   <span class="font10">Case </span>
   <span class="font10">Clinic, </span>
   <span class="font10">European </span>
   <span class="font10">HA-related </span>
   <span class="font10">Institute </span>
   <span class="font10">International </span>
   <span class="font10">Korea; </span>
   <span class="font10">Korean </span>
   <span class="font10">PROMISE- </span>
   <span class="font10">PoTS </span>
   <span class="font10">Sciences, </span>
   <span class="font10">Teva. </span>
   <span class="font10">assess </span>
   <span class="font10">children’s </span>
   <span class="font10">content </span>
   <span class="font10">disorder </span>
   <span class="font10">employees </span>
   <span class="font10">evaluated </span>
   <span class="font10">followed </span>
   <span class="font10">headaches, </span>
   <span class="font10">important </span>
   <span class="font10">improvement </span>
   <span class="font10">individuals </span>
   <span class="font10">investigate </span>
   <span class="font10">medical </span>
   <span class="font10">migraineurs </span>
   <span class="font10">neurological </span>
   <span class="font10">obtained </span>
   <span class="font10">order </span>
   <span class="font10">outcomes </span>
   <span class="font10">reductions </span>
   <span class="font10">respectively. </span>
   <span class="font10">responder </span>
   <span class="font10">review </span>
   <span class="font10">safety </span>
   <span class="font10">second </span>
   <span class="font10">supraorbital </span>
   <span class="font10">thyroid </span>
   <span class="font10">underwent </span>
   <span class="font10">visit </span>
   <span class="font10">visits </span>
   <span class="font10">Abstract </span>
   <span class="font10">Amgen, </span>
   <span class="font10">BioPharmaceuticals, </span>
   <span class="font10">Bothell, </span>
   <span class="font10">Conclusion: </span>
   <span class="font10">Discussion </span>
   <span class="font10">EDS </span>
   <span class="font10">Massimiliano </span>
   <span class="font10">Methods </span>
   <span class="font10">Pharma </span>
   <span class="font10">Pharma, </span>
   <span class="font10">Roger </span>
   <span class="font10">[.-.]), </span>
   <span class="font10">adults </span>
   <span class="font10">analyses </span>
   <span class="font10">analyzed </span>
   <span class="font10">attacks </span>
   <span class="font10">cases. </span>
   <span class="font10">cerebellar </span>
   <span class="font10">changes </span>
   <span class="font10">correlation </span>
   <span class="font10">daily </span>
   <span class="font10">diagnosed </span>
   <span class="font10">disorders </span>
   <span class="font10">does </span>
   <span class="font10">drugs </span>
   <span class="font10">eptinezumab </span>
   <span class="font10">features </span>
   <span class="font10">fees </span>
   <span class="font10">findings </span>
   <span class="font10">general </span>
   <span class="font10">groups </span>
   <span class="font10">healthy </span>
   <span class="font10">incidence </span>
   <span class="font10">left </span>
   <span class="font10">main </span>
   <span class="font10">maternal </span>
   <span class="font10">median </span>
   <span class="font10">men </span>
   <span class="font10">new </span>
   <span class="font10">platform </span>
   <span class="font10">presented </span>
   <span class="font10">px; </span>
   <span class="font10">role </span>
   <span class="font10">sensitization </span>
   <span class="font10">specific </span>
   <span class="font10">suffering </span>
   <span class="font10">toxin </span>
   <span class="font10">trial </span>
   <span class="font10">{font-family </span>
   <span class="font10">(CM) </span>
   <span class="font10">(EM) </span>
   <span class="font10">-year-old </span>
   <span class="font10">.%, </span>
   <span class="font10">.), </span>
   <span class="font10">Analysis </span>
   <span class="font10">Athens </span>
   <span class="font10">Background </span>
   <span class="font10">Cho </span>
   <span class="font10">Clinic </span>
   <span class="font10">Conclusions: </span>
   <span class="font10">DBTP </span>
   <span class="font10">HCDs </span>
   <span class="font10">Kyung </span>
   <span class="font10">MA; </span>
   <span class="font10">Mean </span>
   <span class="font10">Min </span>
   <span class="font10">Neurological </span>
   <span class="font10">Pavia, </span>
   <span class="font10">States; </span>
   <span class="font10">Statistical </span>
   <span class="font10">USA; </span>
   <span class="font10">Week </span>
   <span class="font10">acute </span>
   <span class="font10">adult </span>
   <span class="font10">assessed </span>
   <span class="font10">better </span>
   <span class="font10">collected </span>
   <span class="font10">defined </span>
   <span class="font10">digital </span>
   <span class="font10">disorders. </span>
   <span class="font10">failures </span>
   <span class="font10">font-size </span>
   <span class="font10">headache: </span>
   <span class="font10">honoraria </span>
   <span class="font10">identify </span>
   <span class="font10">levels </span>
   <span class="font10">mg, </span>
   <span class="font10">occipital </span>
   <span class="font10">odds </span>
   <span class="font10">patients, </span>
   <span class="font10">patients; </span>
   <span class="font10">period </span>
   <span class="font10">placebo, </span>
   <span class="font10">pressure </span>
   <span class="font10">prospective </span>
   <span class="font10">regarding </span>
   <span class="font10">right </span>
   <span class="font10">sTMS </span>
   <span class="font10">sensitivity </span>
   <span class="font10">stimulation </span>
   <span class="font10">temporal </span>
   <span class="font10">therapy </span>
   <span class="font10">years. </span>
   <span class="font10">(.% </span>
   <span class="font10">(., </span>
   <span class="font10">(MMDs) </span>
   <span class="font10">(PROMISE-) </span>
   <span class="font10">(mg) </span>
   <span class="font10">(p= </span>
   <span class="font10">AG, </span>
   <span class="font10">BTX-A </span>
   <span class="font10">BVM </span>
   <span class="font10">Basel, </span>
   <span class="font10">Brain </span>
   <span class="font10">Classification </span>
   <span class="font10">Compared </span>
   <span class="font10">Data </span>
   <span class="font10">Faculty </span>
   <span class="font10">ICHD- </span>
   <span class="font10">Institute, </span>
   <span class="font10">Italy </span>
   <span class="font10">Joshua </span>
   <span class="font10">London, </span>
   <span class="font10">Maria </span>
   <span class="font10">Mitsikostas </span>
   <span class="font10">Patricia </span>
   <span class="font10">School, </span>
   <span class="font10">Soo-Jin </span>
   <span class="font10">Tehran, </span>
   <span class="font10">Teva, </span>
   <span class="font10">Typical </span>
   <span class="font10">Vall </span>
   <span class="font10">activity </span>
   <span class="font10">administered </span>
   <span class="font10">aura, </span>
   <span class="font10">bilateral </span>
   <span class="font10">centres </span>
   <span class="font10">cortex </span>
   <span class="font10">day </span>
   <span class="font10">decrease </span>
   <span class="font10">determine </span>
   <span class="font10">dietary </span>
   <span class="font10">differences </span>
   <span class="font10">double; </span>
   <span class="font10">endpoint </span>
   <span class="font10">enrolled </span>
   <span class="font10">especially </span>
   <span class="font10">estimate </span>
   <span class="font10">evaluate </span>
   <span class="font10">events </span>
   <span class="font10">examined </span>
   <span class="font10">factors </span>
   <span class="font10">follow-up </span>
   <span class="font10">funded </span>
   <span class="font10">group. </span>
   <span class="font10">groups. </span>
   <span class="font10">initial </span>
   <span class="font10">level </span>
   <span class="font10">life </span>
   <span class="font10">majority </span>
   <span class="font10">medication. </span>
   <span class="font10">monoclonal </span>
   <span class="font10">need </span>
   <span class="font10">neuralgia </span>
   <span class="font10">occurred </span>
   <span class="font10">onset </span>
   <span class="font10">overall </span>
   <span class="font10">patient. </span>
   <span class="font10">points </span>
   <span class="font10">population-based </span>
   <span class="font10">potential </span>
   <span class="font10">predictors </span>
   <span class="font10">rate </span>
   <span class="font10">reduced </span>
   <span class="font10">risk </span>
   <span class="font10">sample </span>
   <span class="font10">scales </span>
   <span class="font10">stress </span>
   <span class="font10">suggest </span>
   <span class="font10">tension-type </span>
   <span class="font10">testing </span>
   <span class="font10">topiramate </span>
   <span class="font10">unilateral </span>
   <span class="font10">visiting </span>
   <span class="font10">week </span>
   <span class="font10">year </span>
   <span class="font10">(mean </span>
   <span class="font10">(n=) </span>
   <span class="font10">(range </span>
   <span class="font10">,*, </span>
   <span class="font10">Aeginition </span>
   <span class="font10">CM. </span>
   <span class="font10">CVS </span>
   <span class="font10">Child </span>
   <span class="font10">EM. </span>
   <span class="font10">Finally, </span>
   <span class="font10">Funding </span>
   <span class="font10">García-Azorín </span>
   <span class="font10">Greece; </span>
   <span class="font10">Kim </span>
   <span class="font10">MMD, </span>
   <span class="font10">Neuroscience </span>
   <span class="font10">Paolo </span>
   <span class="font10">Pharmaceuticals </span>
   <span class="font10">Pharmaceuticals. </span>
   <span class="font10">Physical </span>
   <span class="font10">References </span>
   <span class="font10">SPAIN; </span>
   <span class="font10">Sciences </span>
   <span class="font10">Spain; </span>
   <span class="font10">States </span>
   <span class="font10">TBI </span>
   <span class="font10">Test </span>
   <span class="font10">Total </span>
   <span class="font10">USA </span>
   <span class="font10">VAS </span>
   <span class="font10">Yang </span>
   <span class="font10">[.-.]). </span>
   <span class="font10">[.-.]; </span>
   <span class="font10">active </span>
   <span class="font10">administration </span>
   <span class="font10">ago </span>
   <span class="font10">alexithymia </span>
   <span class="font10">and/or </span>
   <span class="font10">anterior </span>
   <span class="font10">anxiety </span>
   <span class="font10">autonomic </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">completed </span>
   <span class="font10">considered </span>
   <span class="font10">consistent </span>
   <span class="font10">cortical </span>
   <span class="font10">current </span>
   <span class="font10">days, </span>
   <span class="font10">demonstrated </span>
   <span class="font10">depressive </span>
   <span class="font10">downloads </span>
   <span class="font10">drug </span>
   <span class="font10">effective </span>
   <span class="font10">end </span>
   <span class="font10">episodes </span>
   <span class="font10">examination </span>
   <span class="font10">excellent </span>
   <span class="font10">experience </span>
   <span class="font10">expression </span>
   <span class="font10">extent </span>
   <span class="font10">found. </span>
   <span class="font10">frequently </span>
   <span class="font10">fruits </span>
   <span class="font10">functional </span>
   <span class="font10">group, </span>
   <span class="font10">having </span>
   <span class="font10">improved </span>
   <span class="font10">increasing </span>
   <span class="font10">individual </span>
   <span class="font10">intake </span>
   <span class="font10">investigated </span>
   <span class="font10">likely </span>
   <span class="font10">mechanisms </span>
   <span class="font10">member </span>
   <span class="font10">members </span>
   <span class="font10">metabolism </span>
   <span class="font10">needed </span>
   <span class="font10">nerve </span>
   <span class="font10">novel </span>
   <span class="font10">nurse </span>
   <span class="font10">objective </span>
   <span class="font10">osmophobia </span>
   <span class="font10">p=.) </span>
   <span class="font10">p=.), </span>
   <span class="font10">past </span>
   <span class="font10">pathogenesis </span>
   <span class="font10">patients’ </span>
   <span class="font10">performance </span>
   <span class="font10">phase </span>
   <span class="font10">possible </span>
   <span class="font10">presence </span>
   <span class="font10">prevalent </span>
   <span class="font10">profile </span>
   <span class="font10">provided </span>
   <span class="font10">real-world </span>
   <span class="font10">reducing </span>
   <span class="font10">refractory </span>
   <span class="font10">related </span>
   <span class="font10">report </span>
   <span class="font10">revealed </span>
   <span class="font10">series </span>
   <span class="font10">set </span>
   <span class="font10">sham </span>
   <span class="font10">shown </span>
   <span class="font10">small </span>
   <span class="font10">social </span>
   <span class="font10">solid; </span>
   <span class="font10">specialist </span>
   <span class="font10">start </span>
   <span class="font10">study, </span>
   <span class="font10">suggests </span>
   <span class="font10">symptom </span>
   <span class="font10">symptomatic </span>
   <span class="font10">syndrome </span>
   <span class="font10">tertile </span>
   <span class="font10">tests </span>
   <span class="font10">treatment. </span>
   <span class="font10">usually </span>
   <span class="font10">vegetables </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">&amp;gt;y, </span>
   <span class="font10">(.%, </span>
   <span class="font10">(.), </span>
   <span class="font10">(Abstract </span>
   <span class="font10">(N=) </span>
   <span class="font10">(PROMISE-; </span>
   <span class="font10">(SD) </span>
   <span class="font10">(T: </span>
   <span class="font10">(TTH) </span>
   <span class="font10">(from </span>
   <span class="font10">(mg); </span>
   <span class="font10">(mg, </span>
   <span class="font10">(p&amp;lt;.). </span>
   <span class="font10">(p=.) </span>
   <span class="font10">(p=.), </span>
   <span class="font10">(p=.). </span>
   <span class="font10">-.; </span>
   <span class="font10">-GR, </span>
   <span class="font10">.±., </span>
   <span class="font10">A). </span>
   <span class="font10">Angeliki </span>
   <span class="font10">Autonomic </span>
   <span class="font10">BPT </span>
   <span class="font10">Background. </span>
   <span class="font10">Bambino </span>
   <span class="font10">Behavioral </span>
   <span class="font10">Bougea </span>
   <span class="font10">Bundang </span>
   <span class="font10">Cady </span>
   <span class="font10">Change </span>
   <span class="font10">Characteristics </span>
   <span class="font10">Charly </span>
   <span class="font10">Christian </span>
   <span class="font10">Chu </span>
   <span class="font10">Consulting, </span>
   <span class="font10">David </span>
   <span class="font10">ER/UC </span>
   <span class="font10">Eginition </span>
   <span class="font10">Electrocore, </span>
   <span class="font10">Emma </span>
   <span class="font10">Eric </span>
   <span class="font10">Europe </span>
   <span class="font10">France; </span>
   <span class="font10">Frey </span>
   <span class="font10">Functional </span>
   <span class="font10">Gaul </span>
   <span class="font10">Given </span>
   <span class="font10">HURT </span>
   <span class="font10">Hamilton </span>
   <span class="font10">Headache-Sleep </span>
   <span class="font10">Heart </span>
   <span class="font10">Hemiplegic </span>
   <span class="font10">IRCCS, </span>
   <span class="font10">IV, </span>
   <span class="font10">Iran; </span>
   <span class="font10">Japan </span>
   <span class="font10">Josefin </span>
   <span class="font10">LIBERTY </span>
   <span class="font10">LLC, </span>
   <span class="font10">Laura </span>
   <span class="font10">Lucas </span>
   <span class="font10">METHODS </span>
   <span class="font10">MRI </span>
   <span class="font10">Madrid, </span>
   <span class="font10">Martelletti </span>
   <span class="font10">Methods. </span>
   <span class="font10">Michel </span>
   <span class="font10">Months </span>
   <span class="font10">Munoz-Delgado, </span>
   <span class="font10">NH. </span>
   <span class="font10">Nearly </span>
   <span class="font10">Nocebo </span>
   <span class="font10">None. </span>
   <span class="font10">Novartis. </span>
   <span class="font10">Nummular </span>
   <span class="font10">OLEP, </span>
   <span class="font10">Objective: </span>
   <span class="font10">Overall, </span>
   <span class="font10">PHQ- </span>
   <span class="font10">PRO </span>
   <span class="font10">PROMISE-), </span>
   <span class="font10">Pacific </span>
   <span class="font10">Patient </span>
   <span class="font10">PoTS, </span>
   <span class="font10">Pozo-Rosich </span>
   <span class="font10">Primary </span>
   <span class="font10">RESULTS </span>
   <span class="font10">Raieli </span>
   <span class="font10">Ramsden </span>
   <span class="font10">Relivion® </span>
   <span class="font10">Republic </span>
   <span class="font10">Results. </span>
   <span class="font10">Romina </span>
   <span class="font10">Scale </span>
   <span class="font10">Seoul </span>
   <span class="font10">Seoul, </span>
   <span class="font10">Service </span>
   <span class="font10">Severance </span>
   <span class="font10">Shannon </span>
   <span class="font10">Sleep </span>
   <span class="font10">Snellman </span>
   <span class="font10">Springer </span>
   <span class="font10">Stephen </span>
   <span class="font10">Switzerland; </span>
   <span class="font10">TTH, </span>
   <span class="font10">Tae-Jin </span>
   <span class="font10">Tehran </span>
   <span class="font10">USA. </span>
   <span class="font10">Unit </span>
   <span class="font10">Universidad </span>
   <span class="font10">Using </span>
   <span class="font10">VIP </span>
   <span class="font10">VIP, </span>
   <span class="font10">Valeriani </span>
   <span class="font10">Valeriani( </span>
   <span class="font10">Visual </span>
   <span class="font10">Watson </span>
   <span class="font10">Written, </span>
   <span class="font10">Yonsei </span>
   <span class="font10">advisory </span>
   <span class="font10">analogue </span>
   <span class="font10">antibodies </span>
   <span class="font10">appropriate </span>
   <span class="font10">assessment </span>
   <span class="font10">available </span>
   <span class="font10">based </span>
   <span class="font10">bilaterally </span>
   <span class="font10">bold </span>
   <span class="font10">cause </span>
   <span class="font10">central </span>
   <span class="font10">characterized </span>
   <span class="font10">classified </span>
   <span class="font10">cognitive </span>
   <span class="font10">comorbid </span>
   <span class="font10">concomitant </span>
   <span class="font10">conditions </span>
   <span class="font10">confirm </span>
   <span class="font10">consent </span>
   <span class="font10">consumption </span>
   <span class="font10">continuous </span>
   <span class="font10">courier; </span>
   <span class="font10">course </span>
   <span class="font10">dedicated </span>
   <span class="font10">depressed </span>
   <span class="font10">develop </span>
   <span class="font10">disease. </span>
   <span class="font10">disturbances </span>
   <span class="font10">educational </span>
   <span class="font10">effects </span>
   <span class="font10">electroCore, </span>
   <span class="font10">em; </span>
   <span class="font10">evolution </span>
   <span class="font10">exhibited </span>
   <span class="font10">extra-trigeminal </span>
   <span class="font10">facial </span>
   <span class="font10">failures. </span>
   <span class="font10">failures: </span>
   <span class="font10">feeling </span>
   <span class="font10">fiber </span>
   <span class="font10">frequency, </span>
   <span class="font10">fruit </span>
   <span class="font10">gene-related </span>
   <span class="font10">genetic </span>
   <span class="font10">grade </span>
   <span class="font10">grants </span>
   <span class="font10">gyrus </span>
   <span class="font10">headache-free </span>
   <span class="font10">hospital </span>
   <span class="font10">indicates </span>
   <span class="font10">informed </span>
   <span class="font10">initiated </span>
   <span class="font10">intrinsic </span>
   <span class="font10">investigator </span>
   <span class="font10">iron </span>
   <span class="font10">item </span>
   <span class="font10">light </span>
   <span class="font10">limbs </span>
   <span class="font10">low </span>
   <span class="font10">magnetic </span>
   <span class="font10">meet </span>
   <span class="font10">meta-analysis </span>
   <span class="font10">neuromodulation </span>
   <span class="font10">nights </span>
   <span class="font10">non-headache </span>
   <span class="font10">non-invasive </span>
   <span class="font10">normal. </span>
   <span class="font10">nucleus, </span>
   <span class="font10">numerically </span>
   <span class="font10">occur </span>
   <span class="font10">onabotulinum </span>
   <span class="font10">open-label </span>
   <span class="font10">outpatient </span>
   <span class="font10">overnight </span>
   <span class="font10">p&amp;lt;.), </span>
   <span class="font10">p&amp;lt;.). </span>
   <span class="font10">painful </span>
   <span class="font10">paralysis </span>
   <span class="font10">particular </span>
   <span class="font10">patient-reported </span>
   <span class="font10">percentage </span>
   <span class="font10">period, </span>
   <span class="font10">phono-, </span>
   <span class="font10">photo-, </span>
   <span class="font10">place </span>
   <span class="font10">placebo-treated </span>
   <span class="font10">population, </span>
   <span class="font10">population. </span>
   <span class="font10">positive </span>
   <span class="font10">proper </span>
   <span class="font10">psychiatric </span>
   <span class="font10">pt;} </span>
   <span class="font10">publication </span>
   <span class="font10">questionnaire </span>
   <span class="font10">questionnaires </span>
   <span class="font10">range </span>
   <span class="font10">rare </span>
   <span class="font10">rates </span>
   <span class="font10">rcady@alderbio.com) </span>
   <span class="font10">receive </span>
   <span class="font10">recruited </span>
   <span class="font10">referred </span>
   <span class="font10">region </span>
   <span class="font10">relevant </span>
   <span class="font10">reports </span>
   <span class="font10">represents </span>
   <span class="font10">resonance </span>
   <span class="font10">respectively). </span>
   <span class="font10">screened </span>
   <span class="font10">section </span>
   <span class="font10">seen </span>
   <span class="font10">severity </span>
   <span class="font10">similar </span>
   <span class="font10">subgroup </span>
   <span class="font10">subgroups </span>
   <span class="font10">susceptibility </span>
   <span class="font10">sustained </span>
   <span class="font10">symptoms, </span>
   <span class="font10">tertiary </span>
   <span class="font10">therapeutic </span>
   <span class="font10">threshold </span>
   <span class="font10">took </span>
   <span class="font10">trauma. </span>
   <span class="font10">traumatic </span>
   <span class="font10">uploads </span>
   <span class="font10">useful </span>
   <span class="font10">value </span>
   <span class="font10">vascular </span>
   <span class="font10">vegetable </span>
   <span class="font10">von </span>
   <span class="font10">widespread </span>
   <span class="font10">woman </span>
   <span class="font10">women </span>
   <span class="font10">years) </span>
   <span class="font10">years, </span>
   <span class="font10">years; </span>
   <span class="font10">≤y, </span>
  </p>
 </body>
</html>
